SIGNANTHEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals™ Solutions for Schizophrenia

CLINICAL DEVELOPMENT

SOLUTIONS TO IMPROVE SCHIZOPHRENIA STUDY OUTCOMES

Schizophrenia is a leading cause of patient suffering and disability around the world. Despite the compelling, unmet need for new and more effective treatments, the development process remains challenging. Signant Health improves opportunities for study success by applying clinical research technologies and scientific expertise to help researchers address barriers to success.

MANAGE RATER QUALITY TO IMPROVE DATA RELIABILITY

Our solutions provide site indepednent assessment of key eligibility criteria, ensuring that appropriate patients are enrolled, and that raters adhere to scoring and administrative conventions for efficacy outcomes.

MONITOR STUDY DATA AS THEY FLOW IN

By leveraging the most experience and largest data sets in Schizophrenia research, Signant's Blinded Data Analytics solution improves clinical data accuracy and reliability throughout the drug development cycle. Our clinical scientists and operations experts analyze study data at all relevant levels and make recommendations for appropriate interventions.

SIMPLIFY ASSESSMENTS & ADHERENCE FOR PARTICIPANTS

Patient-reported and clinician-reported outcome assessments are vital to fully evaluate schizophrenia treatment efficacy and impact. Our eCOA solution can be tailored to sites' and patient's needs – guided assessments and built-in edit checks reduce COA errors, while alerts and reminders help improve adherence to medication dosing schedules.

SIMPLIFY STUDY MEDICATION MANAGEMENT

Handle the medication management and patient randomization requirements in your protocol with ease. Our RTSM system and powerful algorithms handle complex dosing schedules, patient cohort schemes, and adaptive designs. Plus, our agile implementation model allows for rapid deployment including mid-study amendments.

MAXIMIZE SIGNAL DETECTION OPPORTUNITIES

Talk through your schizophrenia protocol with our science and medicine experts, who serve as an extension of your study team. We guide the selection and acquisition of endpoints and assessments, advise on inclusion/exclusion criteria, and recommend methods to decrease site and participant burdens. Our end goal is to optimize the reliability of your study's endpoint data.

At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for people living with schizophrenia.

SIGNANT'S SCHIZOPHRENIA CLINICAL TRIAL EXPERIENCE

Phases

I II III IV

23 Languages

3,400 Sites

60 Countries

8,500 Patients

147 Protocols

INSTRUMENTS

PANSS | SCI-PANSS | NSA-16 | CGI | PSP

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

RTSM

Scientific Advisory

eCOA

Blinded Data Analytics

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS